Cited 22 times in
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2018-11-23T11:33:23Z | - |
dc.date.available | 2018-11-23T11:33:23Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/165806 | - |
dc.description.abstract | We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse/drug therapy* | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Paranasal Sinus Neoplasms/drug therapy* | - |
dc.subject.MESH | Prednisone/administration & dosage | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Rituximab/administration & dosage | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vincristine/administration & dosage | - |
dc.title | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Gyeong-Won Lee | - |
dc.contributor.googleauthor | Se-Il Go | - |
dc.contributor.googleauthor | Seok-Hyun Kim | - |
dc.contributor.googleauthor | Junshik Hong | - |
dc.contributor.googleauthor | Yu Ri Kim | - |
dc.contributor.googleauthor | Sukjoong Oh | - |
dc.contributor.googleauthor | Sung-Yong Kim | - |
dc.contributor.googleauthor | Young Rok Do | - |
dc.contributor.googleauthor | Hyewon Lee | - |
dc.contributor.googleauthor | Soon Il Lee | - |
dc.contributor.googleauthor | Sung Hwa Bae | - |
dc.contributor.googleauthor | Sung Yong Oh | - |
dc.contributor.googleauthor | Moo Kon Song | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Bohee Lee | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Jae-Sook Ahn | - |
dc.contributor.googleauthor | Ho-Young Yhim | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.identifier.doi | 10.3109/10428194.2014.946027 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J02165 | - |
dc.identifier.eissn | 1029-2403 | - |
dc.identifier.pmid | 25039351 | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.3109/10428194.2014.946027 | - |
dc.subject.keyword | Diffuse large cell lymphomas | - |
dc.subject.keyword | nasal cavities | - |
dc.subject.keyword | paranasal sinus | - |
dc.subject.keyword | rituximab | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 56 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1020 | - |
dc.citation.endPage | 1026 | - |
dc.identifier.bibliographicCitation | LEUKEMIA & LYMPHOMA, Vol.56(4) : 1020-1026, 2015 | - |
dc.identifier.rimsid | 60547 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.